Losartan and end-organ protection--lessons from the RENAAL study.

Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM. Losartan and end-organ protection--lessons from the RENAAL study. Clin Cardiol. 2005 Mar; 28(3):136-42.

View in: PubMed

subject areas

Adult
Aged
Angiotensin II Type 1 Receptor Blockers
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Disease Progression
Female
Humans
Kidney Failure, Chronic
Losartan
Middle Aged
Myocardial Infarction
Proteinuria
Treatment Outcome

authors with profiles

Peter Kowey

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement